SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Van Duijnhoven Franzel J. B.)
 

Sökning: WFRF:(Van Duijnhoven Franzel J. B.) > Polymorphisms in fa...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00010103naa a2200913 4500
001oai:lup.lub.lu.se:4b3a8308-961c-4ff1-97d4-b0ccf1636b9c
003SwePub
008160401s2010 | |||||||||||000 ||eng|
009oai:DiVA.org:umu-31571
0247 a https://lup.lub.lu.se/record/15896842 URI
0247 a https://doi.org/10.1093/carcin/bgp3252 DOI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-315712 URI
040 a (SwePub)lud (SwePub)umu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Hoeft, Birgitu German Cancer Research Center, Heidelberg, Germany4 aut
2451 0a Polymorphisms in fatty acid metabolism-related genes are associated with colorectal cancer risk
264 c 2009-12-30
264 1b Oxford University Press (OUP),c 2010
520 a Colorectal cancer (CRC) is the third most common malignant tumor and the fourth leading cause of cancer death worldwide. The crucial role of fatty acids for a number of important biological processes suggests a more in-depth analysis of inter-individual differences in fatty acid metabolizing genes as contributing factor to colon carcinogenesis. We examined the association between genetic variability in 43 fatty acid metabolism-related genes and colorectal risk in 1225 CRC cases and 2032 controls participating in the European Prospective Investigation into Cancer and Nutrition study. Three hundred and ninety two single-nucleotide polymorphisms were selected using pairwise tagging with an r(2) cutoff of 0.8 and a minor allele frequency of > 5%. Conditional logistic regression models were used to estimate odds ratios and corresponding 95% confidence intervals. Haplotype analysis was performed using a generalized linear model framework. On the genotype level, hydroxyprostaglandin dehydrogenase 15-(NAD) (HPGD), phospholipase A2 group VI (PLA2G6) and transient receptor potential vanilloid 3 were associated with higher risk for CRC, whereas prostaglandin E receptor 2 (PTGER2) was associated with lower CRC risk. A significant inverse association (P < 0.006) was found for PTGER2 GGG haplotype, whereas HPGD AGGAG and PLA2G3 CT haplotypes were significantly (P < 0.001 and P = 0.003, respectively) associated with higher risk of CRC. Based on these data, we present for the first time the association of HPGD variants with CRC risk. Our results support the key role of prostanoid signaling in colon carcinogenesis and suggest a relevance of genetic variation in fatty acid metabolism-related genes and CRC risk.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Linseisen, Jakobu German Cancer Research Center, Heidelberg, Germany4 aut
7001 a Beckmann, Larsu German Cancer Research Center, Heidelberg, Germany4 aut
7001 a Mueller-Decker, Karinu German Cancer Research Center, Heidelberg, Germany4 aut
7001 a Canzian, Federicou German Cancer Research Center, Heidelberg, Germany4 aut
7001 a Huesing, Anikau German Cancer Research Center, Heidelberg, Germany4 aut
7001 a Kaaks, Rudolfu German Cancer Research Center, Heidelberg, Germany4 aut
7001 a Vogel, Ullau National Food Institute, Technical University of Denmark, Soborg, Denmark,National Research Centre for the Working Environment, Copenhagen, Denmark4 aut
7001 a Jakobsen, Marianne U.u Department of Clinical Epidemiology, Aarhus University Hospital, Aalborg, Denmark4 aut
7001 a Overvad, Kimu Department of Clinical Epidemiology, Aarhus University Hospital, Aalborg, Denmark4 aut
7001 a Hansen, Rikke D.u Danish Cancer Society, Copenhagen, Denmark4 aut
7001 a Knueppel, Svenu Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbrücke, Germany4 aut
7001 a Boeing, Heineru Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbrücke, Germany4 aut
7001 a Trichopoulou, Antoniau Department of Hygiene and Epidemiology, University of Athens Medical School, Athens, Greece,Hellenic Health Foundation, Greece4 aut
7001 a Koumantaki, Yvoniu Department of Hygiene and Epidemiology, University of Athens Medical School, Athens, Greece4 aut
7001 a Trichopoulos, Dimitriosu Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA4 aut
7001 a Berrino, Francou Etiological Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy4 aut
7001 a Palli, Domenicou Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute – ISPO, Florence, Italy4 aut
7001 a Panico, Salvatoreu Department of Clinical and Experimental Medicine, Federico II University, Naples, Italy4 aut
7001 a Tumino, Rosariou Cancer Registry and Histopathology Unit, Department of Oncology , “Civile - M.P.Arezzo” Hospital, Ragusa, Italy4 aut
7001 a Bueno-de-Mesquita, H. B.u National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands4 aut
7001 a van Duijnhoven, Franzel J. B.u National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands4 aut
7001 a van Gils, Carla H.u Julius Center, University Medical Center Utrecht, Utrecht, The Netherlands4 aut
7001 a Peeters, Petra H.u Julius Center, University Medical Center Utrecht, Utrecht, The Netherlands,Division of Epidemiology, Public Health and Primary Care, Imperial College London, London, UK4 aut
7001 a Dumeaux, Vanessau Institute of Community Medicine, University of Tromsø, Norway4 aut
7001 a Lund, Eilivu Institute of Community Medicine, University of Tromsø, Norway4 aut
7001 a Huerta Castano, Jose M.u CIBER Epidemiología y Salud Pública, CIBERESP, Spain,Council of Health and Consumer Affairs, Murcia, Spain4 aut
7001 a Munoz, Xavieru Research Laboratory and Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Programme, IDIBELL-Catalan Institute of Oncology, Barcelona, Spain4 aut
7001 a Rodriguez, Laudinau Public Health and Participation Directorate, Health and Health Care Services Council, Asturias, Spain4 aut
7001 a Barricarte, Aureliou CIBER Epidemiología y Salud Pública, CIBERESP, Spain,Public Health Institute of Navarra, Pamplona, Spain4 aut
7001 a Manjer, Jonasu Lund University,Lunds universitet,Kirurgi,Forskargrupper vid Lunds universitet,Surgery,Lund University Research Groups,Department of Surgery, Malmö University Hospital, Malmö, Sweden4 aut0 (Swepub:lu)smi-jma
7001 a Jirström, Karinu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Center for Molecular Pathology, Department of Laboratory Medicine, Malmö University Hospital, Lund University, Malmö Sweden,CREATE Health Center for Translational Cancer Research, Biomedical Center, Lund University, Lund, Sweden4 aut0 (Swepub:lu)pat-kji
7001 a Van Guelpen, Bethanyu Umeå universitet,Patologi4 aut0 (Swepub:umu)beyvan99
7001 a Hallmans, Göran,d 1947-u Umeå universitet,Näringsforskning4 aut0 (Swepub:umu)goha0001
7001 a Spencer, Elizabeth A.u Cancer Epidemiology Unit, University of Oxford, Oxford, UK4 aut
7001 a Crowe, Francesca L.u Cancer Epidemiology Unit, University of Oxford, Oxford, UK4 aut
7001 a Khaw, Kay-Teeu Department of Public Health and Primary Care, University of Cambridge4 aut
7001 a Wareham, Nicku Medical Research Council (MRC) Epidemiology Unit, Cambridge, UK4 aut
7001 a Morois, Sophieu Inserm, (Institut National de la Santé et de la Recherche Médicale), and Institut Gustave Roussy, Villejuif, France4 aut
7001 a Boutron-Ruault, Marie-Christineu Inserm, (Institut National de la Santé et de la Recherche Médicale), and Institut Gustave Roussy, Villejuif, France4 aut
7001 a Clavel-Chapelon, Francoiseu Inserm, (Institut National de la Santé et de la Recherche Médicale), and Institut Gustave Roussy, Villejuif, France4 aut
7001 a Chajes, Veroniqueu International Agency for Research on Cancer (IARC), Lyon, France4 aut
7001 a Jenab, Mazdau International Agency for Research on Cancer (IARC), Lyon, France4 aut
7001 a Boffetta, Paolou International Agency for Research on Cancer (IARC), Lyon, France4 aut
7001 a Vineis, Paolou Cancer Epidemiology Department, University of Turin, Turin, Italy,Division of Epidemiology, Public Health and Primary Care, Imperial College London, London, UK4 aut
7001 a Mouw, Traciu Division of Epidemiology, Public Health and Primary Care, Imperial College London, London, UK4 aut
7001 a Norat, Teresau Division of Epidemiology, Public Health and Primary Care, Imperial College London, London, UK4 aut
7001 a Riboli, Eliou Division of Epidemiology, Public Health and Primary Care, Imperial College London, London, UK4 aut
7001 a Nieters, Alexandrau German Cancer Research Center, Heidelberg, Germany,Centre of Chronic Immunodeficiency, University of Freiburg Medical Centre, Freiburg, Germany4 aut
7102 a German Cancer Research Center, Heidelberg, Germanyb National Food Institute, Technical University of Denmark, Soborg, Denmark4 org
7730 t Carcinogenesisd : Oxford University Press (OUP)g 31:3, s. 466-472q 31:3<466-472x 0143-3334x 1460-2180
8564 u http://dx.doi.org/10.1093/carcin/bgp325y FULLTEXT
8564 u https://academic.oup.com/carcin/article-pdf/31/3/466/17288228/bgp325.pdf
8564 8u https://lup.lub.lu.se/record/1589684
8564 8u https://doi.org/10.1093/carcin/bgp325
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-31571

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy